Clinical guidelines
1,2 advocate the use of oral anticoagulation, whether a vitamin K antagonist (VKA) or one of the novel agents, for stroke prevention in patients with atrial fibrillation (AF) who have one or more risk factor for stroke. The benefits of traditional oral anticoagulants (VKAs), in terms of a reduction in stroke and major bleeding events, are only experienced over a narrow therapeutic window (International Normalised Ratio (INR) of 2.0 to 3.0). Their intricate pharmacokinetic profile with a slow onset and offset of action and numerous drug-, food-and alcohol-interactions, as well as genetic, ethnicity, and age-related differences in dose response, necessitates regular INR monitoring 3 .
The efficacy and safety of VKAs strongly depends upon the percentage of time in the therapeutic range (TTR) (INR 2.0 to 3.0), with maximum benefits evident when the TTR is 70%
and greater [4] [5] [6] . It is well known that poor control of anticoagulation intensity increases the risks of both thrombotic and hemorrhagic events [4] [5] [6] . These inherent limitations associated with VKAs have prompted the development of novel oral anticoagulants (NOACs), targeting a specific factor of the coagulation pathway, and providing a stable anticoagulation effect with a fixed dose. Over the past few years, NOACs have yielded encouraging results, demonstrating at least non-inferiority to warfarin for stroke and systemic embolism and major bleeding 7 and for some endpoints, superior efficacy 7 and/or safety 7 . However, it has been suggested that the beneficial effect of the NOACs could be simply due to sub-optimal control of the INR among patients in the warfarin arms of these trials.
In this issue of Circulation, this important issue is addressed by Wallentin et al 8 in a posthoc analysis of the ARISTOTLE cohort of 18,201 AF patients with 1 risk factor for stroke who were randomised to receive either apixaban 5mg twice daily or dose-adjusted warfarin for stroke prevention, in over 1000 clinical centres in 39 countries, followed up over a median of 1.8 years.
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The present analyses examined the relationship between the stroke and systemic embolism, major bleeding, and deathfrom any cause, with INR control, evidenced by percentage TTR quantified asboth centre TTR (cTTR) and individual TTR (iTTR) 8 .
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Although major bleeding was significantly lower with apixaban compared to warfarin [HR 0.69; 95% CI0.60-0.80) 10 overall and across quartiles of predicted cTTR 8 , the benefit of apixaban was greatest at centres with the lowest predicted TTR. However, the rate of major bleeding appeared to be greatest in those centres with the best INR control (cTTR>71.2%), which could be explained by better compliance in bleeding event reporting at sites with high TTR. Despite this anomaly, a significant net clinical benefit in favour of apixaban was evident for those centres with the poorest cTTR ( 60.5).
The analyses of predicted cTTR demonstrate that the benefit of apixaban on all the outcomes reported in these post-hoc analyses, with the exception of mortality, are more pronounced among those patients with cTTR 60.5%. Comparable results were reported in similar analyses of cTTR comparing dabigatran to warfarin 9 : when compared to warfarin either doses of dabigatran reduced the risk of stroke and systemic embolism or major bleeding among patients with low cTTR (<57%). Nonetheless, it should be remembered that cTTR is primarily a reflection of differences in the quality of oral anticoagulant services, which is contingent on the provision of service, accessibility for patients, costs incurred attending for INR checks etc, all of which may be better in more affluent countries, and does not take into consideration individual differences in INR control.
Importantly, the present post-hoc analyses also examined the impact of predicted iTTR on outcomes. Among patients receiving warfarin the median (IQR) predicted iTTR was 66.0%
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These sub-analyses reported by Wallentin and colleagues 8 highlight two important points.
First, they reiterate and further emphasize the importance of achieving and maintaining the optimum INR (target 2.5, range 2.0-3.0) with the generally corresponding lower adverse event rates evident with good TTR, which corroborates previous findings by other secondary analyses of trial cohorts 9,11-12 , a retrospective observational study 13 and systematic reviews and metaanalyses 6, 14 . Therefore, every effort should be made to achieve and sustain therapeutic anticoagulation control for patients receiving VKAs. Second, these results strengthen the main findings from the ARISTOTLE trial 10 and demonstrate the superior efficacy and safety of apixaban over warfarin, even when compared to optimal anticoagulation with warfarin (TTR 70%), suggesting that the benefits of NOACs are not simply a result of sub-optimal INR control in the trials 8, 9 .
Finally, it is worth noting that perhaps the most important question resulting from the analyses of Wallentin et al is that of TTR prediction 8 . Until now, when prescribing oral anticoagulation, physicians have not been able to reliably predict which patients will be able to tolerate a VKA, who would be able to achieve and maintain steady INR control, and thus benefit First, they reiterate and further emphasize the importance of achieving and maint nt tai a aini ni n ng ng ng t t the he he optimum INR (target 2.5, range 2.0-3.0) with the generally corresponding lower adverse event a ate te es s s ev ev evid id iden en ent t t wi w th th h g go ood TTR, which corroborates es es p pr revious findin ngs g g by y ot ot othe h r secondary analyses of f t tr ri rial cohorts ts 9,1 9,1 9,11-1 12 , a a a re e etr r tros os ospe pe pect ctiv iv ve e e ob ob bs se erva a atio onal l l s stud d dy y y 1 13 13 a a and nd d s sy y yst te tema mati t c c c re re evi vi view ews s s an an nd d d me me meta ta--an nal al alys ys yses es e 6, 14 14 . Th The e ere ef efor ore e, e eve v ry ry y e eff ff ffor or ort t t sh sh hou ou uld ld ld b be e e ma ma mad de e to o o ac ac ach hi hiev v ve e e a an and d d su su s s s sta ai ain n th th t e er erap ap apeu eu utic c c anticoagulatio io on n n co co ont nt ntro ro ol l fo f r r r pa pa patien en ents ts t r r rec ec cei ei e vi vi ving ng ng V V VKA KA KAs. s. . S Sec ec econ on ond, d, d t t the he hese e e r r res es esul ul ults ts ts s s str tren en engt gt gthe he hen n n the main from VKA, and those cases in whom reaching a therapeutic dose would be difficult or impossible to achieve. Therefore efforts to identify those patients who may be more or less likely to achieve a good TTR should be concentrated on, as this would assist in the decision-making process about the most appropriate oral anticoagulant for each patient, given the greater choice of agents currently available.
Evident from the present analyses 8 and previous meta-analyses 14, 15 , demonstrates that the quality of oral anticoagulation is strongly related to the performance of coagulation centre and to clinical and demographic characteristics inherent to each patient. However, how these known characteristics can be applied in daily practice remains unclear.
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